Biohybrid microrobots regulate colonic cytokines and the epithelium barrier in inflammatory bowel disease

Summary

This preclinical study develops an orally delivered biohybrid microrobot to reduce inflammatory cytokines in the colon and support epithelial repair in inflammatory bowel disease. The system combines motile green microalgae with nanoparticles coated in macrophage membrane, which presents binding sites for multiple proinflammatory mediators. As the algae move, the attached particles capture cytokines throughout the local environment rather than remaining as a stationary scavenger. The authors report that these dynamic constructs removed cytokines more effectively than static counterparts because they moved continuously, distributed more broadly, and remained longer in the colon. An oral capsule protected the system from stomach acidity and released functional robots at the intended intestinal site. In a mouse model of IBD, the treatment regulated cytokine levels, promoted healing of the damaged epithelial barrier, and improved both preventive and therapeutic outcomes, with a favorable reported biosafety profile. The principal finding is that biological motion can enhance membrane-based cytokine scavenging after oral delivery. This links active transport with immune modulation in the gut, although the abstract does not specify disease scores, individual cytokines, microbiome effects, long-term safety, or comparison with standard IBD medicines.